GLP-1 receptor agonist drugs, used for the treatment of diabetes—and more recently, weight loss—are associated with a ...

A consensus statement providing novel guidance for use of GLP-1 and GLP-1/GIP receptor agonists (GLP-1s and GIP/GLP-1s) in management of type 1 diabetes (T1D) was published today in Diabetes ...

Psoriasis and psoriatic arthritis (PsA) are chronic, immune-mediated inflammatory diseases associated with several shared common comorbidities, of which obesity is one of the most prevalent. A complex ...

GLP-1 receptor agonist drugs, used for the treatment of diabetes, and more recently, weight loss, are associated with a ...

GLP-1 RAs are associated with a significantly reduced risk for post-ERCP pancreatitis and related adverse events.

Please provide your email address to receive an email when new articles are posted on . A link was found between GLP-1 receptor agonist use in PAH and significant decreases in mortality, respiratory ...

In children and adolescents with type 2 diabetes (T2D) or obesity, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) improve glycemic, weight, and cardiometabolic outcomes, according to a study ...

GLP-1 RA use was also tied to lower rates of immune-related side effects, caused by the immune system becoming overactive as a result of immunotherapy treatment. Patients taking GLP-1 drugs showed ...

GLP-1's decrease your appetite for food but perhaps much more as well. Here's what those considering a prescription should ...

U.S. market projected to grow from USD 27.27 billion in 2025 to USD 138.15 billion by 2035 at a 17.61% CAGR, while Europe is expected to rise from USD 16.84 billion to USD 78.24 billion over the same ...

Glucagon-like peptide-1 receptor agonist (GLP-1 RA) exposure is associated with a lower incidence of breast cancer, according ...

Across multiple solid tumors, glucagon-like peptide 1 receptor agonist (GLP-1 RA) initiation after cancer diagnosis is ...